

## FMC Corp (FMC)

**\$95.02** (As of 04/29/20)

Price Target (6-12 Months): **\$100.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 02/12/19)

Prior Recommendation: Underperform

Short Term: 1-3 Months

**Zacks Rank:** (1-5)

**3-Hold**

Zacks Style Scores:

VGM:C

Value: C

Growth: B

Momentum: D

### Summary

Earnings estimates for FMC Corp for the first quarter of 2020 have been going down over the past month. Strong demand for herbicides and insecticides in North and Latin America is likely to support its sales in 2020. Moreover, the company should gain from its efforts to expand product portfolio through new product launches. The acquisition of DuPont's Crop Protection business has also provided a significant growth platform. Synergies from the buyout will drive its earnings. FMC Corp is also committed to boost shareholders' value. However, the company faces headwinds from unfavorable currency translation and higher raw material costs. Higher input costs will hurt revenues and margins. Unfavorable currency is also expected to impact FMC Corp's profits in 2020. High debt level is another matter of concern.


### Price, Consensus & Surprise



### Data Overview

52 Week High-Low	<b>\$108.77 - \$56.77</b>
20 Day Average Volume (sh)	<b>931,354</b>
Market Cap	<b>\$12.3 B</b>
YTD Price Change	<b>-4.8%</b>
Beta	<b>1.32</b>
Dividend / Div Yld	<b>\$1.76 / 1.9%</b>
Industry	<b><u>Chemical - Diversified</u></b>
Zacks Industry Rank	<b>Bottom 29% (179 out of 253)</b>

### Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	<b>15.0%</b>
Last Sales Surprise	<b>0.2%</b>
EPS F1 Est- 4 week change	<b>-2.8%</b>
Expected Report Date	<b>05/05/2020</b>
Earnings ESP	<b>0.0%</b>
P/E TTM	<b>15.6</b>
P/E F1	<b>15.2</b>
PEG F1	<b>1.4</b>
P/S TTM	<b>2.7</b>

### Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	1,298 E	1,323 E	1,097 E	1,309 E	5,041 E
2020	1,248 E	1,219 E	1,038 E	1,237 E	4,722 E
2019	1,192 A	1,206 A	1,014 A	1,197 A	4,610 A

### EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$2.01 E	\$2.05 E	\$1.19 E	\$1.95 E	\$7.19 E
2020	\$1.78 E	\$1.68 E	\$0.97 E	\$1.68 E	\$6.24 E
2019	\$1.72 A	\$1.66 A	\$0.94 A	\$1.76 A	\$6.09 A

\*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 04/29/2020. The reports text is as of 04/30/2020.

## Overview

Based in Philadelphia, PA, FMC Corporation is an agricultural sciences company offering innovative solutions to farmers globally. It has a robust product portfolio and a development pipeline in crop protection, plant health, and professional pest and turf management.

The company's portfolio includes insect control products based on Rynaxypyr and Cyazypyr active ingredients; Talstar and Hero branded insecticides; Authority, Boral, Centium, Command and Gamit branded herbicides; flutriafol-based fungicides; and biologicals such as Quartzo and Presence bionematicides. The company generated revenues of roughly \$4.6 billion in 2019.



FMC Corp, on Mar 1, 2019, completed the final separation of its Lithium division which has been now rebranded as Livent Corporation. The company spun off its roughly 84% stake in Livent to shareholders of FMC Corp in the form of a pro-rata distribution of Livent shares. The separation marked the transformation of FMC Corp into a pure-play agricultural sciences company.

The company operates through a single business segment that is focused on developing and marketing all three major classes of crop protection chemicals, insecticides, herbicides and fungicides. These products have agricultural applications to increase crop yield and quality by controlling a vast spectrum of insects, weeds and disease.

FMC Corp, in April 2015, purchased Denmark-based Auriga Industries' fully-owned unit, Cheminova A/S, for \$1.8 billion (including debt). Cheminova, which has a strong foothold in Europe and Latin America, develops and markets crop protection products.

The acquisition is a strategic fit for FMC Corp as Cheminova has a highly complementary product portfolio and technologies as well as geographic footprint. Cheminova has a portfolio of more than 60 active ingredients, more than 2,300 registrations and a pipeline of active ingredients currently under development.

FMC Corp, in 2017, completed the purchase of a major portion of DuPont's Crop Protection business. Under the deal terms, FMC Corp purchased DuPont's Cereal Broadleaf Herbicides and Chewing Insecticides portfolios as well as substantially all of the latter's crop protection research and development pipeline.



---

## Reasons To Buy:

- ▲ FMC Corp is seeing strong demand for its industry leading products, which is driving its revenues. In Latin America, FMC Corp is witnessing healthy demand from cotton and sugarcane growers in Brazil as well as solid demand for herbicides in soybean applications in Argentina. Strong demand for herbicides and insecticides is also driving the company's agriculture business in North America. It is seeing strength across Rynaxypyr and Cyazypyr insect control products in that region. Strong demand for insecticides is also driving volumes in Asia. The company expects the crop protection market to grow in the low-single digits in 2020 with strongest growth in Asia. It also expects growth in the crop protection market in Brazil to be driven by soybeans and corn.
- ▲ FMC Corp remains committed to expand its market position and strengthen its portfolio. Continued market share gains and new product introductions (across corn, soybean and cotton markets) in North and Latin America are expected to support results in the company's agricultural business. The company remains focused on investing in technologies and products in its agriculture business and launching new products with a goal to enhance value to the farmers. The company plans to invest roughly \$40 million on R&D in 2020. It expects new products to contribute roughly 1.5% of overall volume growth in 2020. New product launches are also expected to contribute to strong volume growth in first-quarter 2020.
- ▲ The company maintains a strategy of growth through acquisitions. The acquisition of Cheminova has expanded FMC Corp.'s access in major agricultural end markets. Moreover, the recently completed acquisition of a major portion of DuPont's Crop Protection business has provided a significant growth platform for the company's Agricultural Solutions unit. The buyout will make the Agricultural Solutions unit the fifth biggest crop protection chemical company in the world by sales and will significantly increase the company's presence in Asia and Europe. The acquisition should contribute to the company's revenues and earnings.
- ▲ FMC Corp remains committed to return value to shareholders leveraging healthy cash flows. It generated free cash flow of \$302 million in 2019 and expects free cash flow of \$425-\$525 million in 2020. The company, in late 2019, hiked its quarterly dividend by 10% to 44 cents per share. The company also repurchased \$400 million of shares in 2019. It also expects to buyback \$400-\$500 million of its shares in 2020.

FMC Corp will benefit from the DuPont assets buyout and efforts to expand product portfolio. Strong demand for herbicides and insecticides across North and Latin America should also drive its sales.

---

## Reasons To Sell:

- ▼ The company is exposed to challenges from higher raw material costs, partly due to supply disruptions from China. The disruptions in that country is likely to be exacerbated by the coronavirus outbreak. The company also faces headwind from higher tariffs. It witnessed an unfavorable impact of \$25 million from raw material cost inflation and tariffs on EBITDA in the last reported quarter. Headwinds related to higher costs were \$167 million in 2019. The company also sees \$32 million cost headwind in the first quarter of 2020, including raw materials and tariffs. FMC Corp envisions raw material cost headwind to persist through the first half of 2020. As such, higher costs will hurt the company's revenues and margins.
- ▼ FMC Corp faces headwind from unfavorable currency translation due to strengthening of the U.S. dollar against a number of major foreign currencies. Currency had an unfavorable impact of 2% on its sales in the most recent quarter and 3% for full-year 2019. Unfavorable impact on EBITDA was \$61 million for 2019. FMC Corp sees currency headwind on EBITDA of \$45 million for full-year 2020. Currency impact for the first quarter is forecast to be \$16 million.
- ▼ The company's high debt level is still a concern. Its total debt of around \$3.3 billion at the end of the fourth quarter of 2019 is significantly higher than its cash and cash equivalent (of around \$339 million). The company has a debt-to-total capital of 56%, which is higher than the industry average of 42.5%. As such, the company appears to have a higher default risk.

FMC Corp is exposed headwind from unfavorable currency translation and higher raw material costs. The company's high debt level is another concern.

## Last Earnings Report

### FMC Corp's Earnings and Revenues Top Estimates in Q4

FMC Corp recorded loss (as reported) of 2 cents per share in fourth-quarter 2019, compared with recast earnings of 24 cents per share a year ago.

Barring one-time items, adjusted earnings per share came in at \$1.76, topping the Zacks Consensus Estimate of \$1.53.

Revenues were \$1,197.3 million for the quarter, up around 9% from the recast figure for the year-ago quarter. It also surpassed the Zacks Consensus Estimate of \$1,194.4 million.

Revenues were aided by high demand across all regions notwithstanding unfavorable weather conditions in Europe and Asia. The company also benefited from its portfolio strength and new technology launches. It saw higher volumes in all regions in the quarter.

Revenue growth was supported by 11% contribution from volume, which was partly offset by a 2% unfavorable impact of currencies. The company achieved higher pricing in Latin America, EMEA (Europe, Middle East, and Africa) and Asia in the reported quarter.

### Full-Year Results

For 2019, earnings (as reported) were \$3.62 per share, compared with \$3.69 per share a year ago.

Revenues were \$4.6 billion for the full year, up around 8% from the recast figure for 2018.

### Regional Sales Performance

Sales in Latin America rose 10% year over year in the reported quarter. This was driven by strong growth in Argentina.

Sales went up 10% year over year in North America, supported by volume gains and strength in Rynaxypyr and Cyazypyr insect controls. In EMEA, sales expanded 5% year over year. This was driven by increased demand for herbicides and insecticides in France and Russia.

Revenues rose 9% year over year in Asia. Sales rose by double-digits in India, China, Indonesia and Pakistan on the back of strong demand for diamides and new product launches.

### Financials

The company had cash and cash equivalents of \$339.1 million at the end of 2019, up 152% year over year. Long-term debt was \$3,031.1 million at the end of the year, up 41% year over year.

The company returned more than \$600 million to shareholders during 2019, including \$400 million in share buybacks.

### Guidance

For 2020, FMC sees revenues to be between \$4.8 billion and \$4.95 billion, indicating a rise of 6% at the midpoint versus 2019.

The company also expects adjusted earnings per share in the range of \$6.45-\$6.70. The guidance reflects an increase of 8% at the midpoint compared with 2019.

Moreover, FMC envisions adjusted EBITDA of \$1.3-\$1.34 billion for 2020, indicating 8% growth at the midpoint versus 2019.

For first-quarter 2020, revenues are projected in the band of \$1.23-\$1.27 billion, indicating 5% growth at the midpoint compared with first-quarter 2019. Adjusted earnings are forecast in the range of \$1.76-\$1.86 per share, reflecting 5% growth at the midpoint compared with first-quarter 2019 figure.

Quarter Ending **12/2019**

Report Date	Feb 05, 2020
Sales Surprise	0.24%
EPS Surprise	15.03%
Quarterly EPS	1.76
Annual EPS (TTM)	6.08

## Valuation

FMC Corp's shares are up 23.4% over the trailing 12-month period. Stocks in the Zacks Chemicals-Diversified industry and the Zacks Basic Materials sector are down 32% and 17.1% over the past year, respectively.

The S&P 500 index is down 2.5% in the past year.

The stock is currently trading at 14.47X forward 12-month earnings, which compares to 14.37X for the Zacks sub-industry, 14.57X for the Zacks sector and 20.16X for the S&P 500 index.

Over the past five years, the stock has traded as high as 36.36X and as low as 8.78X, with a 5-year median of 14.55X.

Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$100 price target reflects 15.22X forward 12-month earnings per share.

The table below shows summary valuation data for FMC:

Valuation Multiples - FMC					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	14.47	14.37	14.57	20.16
	5-Year High	36.36	15.18	21.06	20.16
	5-Year Low	8.78	8.25	9.79	15.19
	5-Year Median	14.55	12.28	13.49	17.45
EV/EBITDA TTM	Current	12.34	6.97	8.81	10.45
	5-Year High	28.64	13.36	18.31	12.87
	5-Year Low	8.63	5.43	6.5	8.27
	5-Year Median	13.56	7.58	10.54	10.78
P/B TTM	Current	4.8	1.45	1.75	3.78
	5-Year High	6.09	3.55	3.57	4.55
	5-Year Low	1.99	0.89	1.22	2.84
	5-Year Median	3.84	1.8	2.17	3.64

As of 04/29/2020

## Industry Analysis Zacks Industry Rank: Bottom 29% (179 out of 253)



## Top Peers

Company (Ticker)	Rec	Rank
Albemarle Corporation (ALB)	Neutral	4
The Chemours Company (CC)	Neutral	3
HITACHI CHEMICAL (HCHMY)	Neutral	1
Methanex Corporation (MEOH)	Neutral	4
Olin Corporation (OLN)	Neutral	3
TOKUYAMA CORP (TKYMY)	Neutral	3
UBE Industries, Ltd. Unsponsored ADR (UBEQY)	Neutral	3
Cabot Corporation (CBT)	Underperform	4

Industry Comparison Industry: Chemical - Diversified				Industry Peers		
	FMC	X Industry	S&P 500	ALB	EMN	SQM
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Underperform	Neutral
Zacks Rank (Short Term)	3	-	-	4	4	3
VGM Score	C	-	-	A	B	F
Market Cap	12.30 B	2.52 B	20.82 B	6.88 B	8.63 B	6.14 B
# of Analysts	10	3	14	10	8	5
Dividend Yield	1.85%	2.37%	2.07%	2.38%	4.16%	2.83%
Value Score	C	-	-	C	A	C
Cash/Price	0.03	0.10	0.06	0.09	0.03	0.10
EV/EBITDA	15.53	7.68	12.12	10.94	8.11	18.10
PEG Ratio	1.39	2.46	2.51	1.52	1.58	2.22
Price/Book (P/B)	4.79	1.58	2.74	1.68	1.43	2.88
Price/Cash Flow (P/CF)	12.86	5.64	11.23	8.01	5.40	22.08
P/E (F1)	14.97	15.88	19.26	14.47	10.07	21.97
Price/Sales (P/S)	2.67	0.83	2.16	1.92	0.93	3.16
Earnings Yield	6.57%	5.98%	5.03%	6.91%	9.93%	4.54%
Debt/Equity	1.18	0.52	0.72	0.70	0.93	0.71
Cash Flow (\$/share)	7.39	3.41	7.01	8.07	11.76	1.06
Growth Score	B	-	-	A	C	F
Hist. EPS Growth (3-5 yrs)	22.23%	9.94%	10.88%	8.83%	1.77%	9.67%
Proj. EPS Growth (F1/F0)	2.41%	-15.61%	-6.94%	-25.99%	-11.57%	0.19%
Curr. Cash Flow Growth	-5.09%	-7.54%	5.92%	6.86%	-9.97%	-36.68%
Hist. Cash Flow Growth (3-5 yrs)	8.36%	6.20%	8.55%	14.46%	1.05%	-1.27%
Current Ratio	1.50	1.87	1.23	1.58	1.86	3.45
Debt/Capital	54.20%	35.68%	43.90%	41.15%	48.19%	41.58%
Net Margin	10.36%	5.03%	11.15%	14.86%	8.19%	14.31%
Return on Equity	29.69%	11.88%	16.47%	16.12%	16.47%	13.01%
Sales/Assets	0.47	0.82	0.54	0.42	0.57	0.42
Proj. Sales Growth (F1/F0)	2.44%	-5.59%	-1.52%	-7.46%	-10.69%	5.77%
Momentum Score	D	-	-	A	B	C
Daily Price Chg	4.54%	3.75%	2.91%	0.56%	4.65%	0.04%
1 Week Price Chg	2.44%	0.65%	-1.74%	0.10%	3.94%	-5.14%
4 Week Price Chg	23.45%	21.44%	21.33%	17.92%	39.46%	12.00%
12 Week Price Chg	-6.68%	-18.06%	-16.28%	-26.16%	-15.90%	-22.93%
52 Week Price Chg	23.43%	-26.36%	-7.57%	-12.69%	-19.20%	-33.61%
20 Day Average Volume	931,354	112,260	2,658,107	1,299,314	1,490,230	704,000
(F1) EPS Est 1 week change	-0.62%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-2.82%	-4.59%	-6.32%	-2.17%	-5.79%	-3.67%
(F1) EPS Est 12 week change	-5.71%	-21.88%	-12.93%	-6.41%	-16.67%	-14.90%
(Q1) EPS Est Mthly Chg	-12.07%	-14.27%	-11.84%	-0.46%	-13.40%	0.00%

---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	B
Momentum Score	D
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

### Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.